Clinical and preclinical studies have linked reduced ApoM expression with cardiometabolic diseases, such as obesity, insulin resistance, type 2 diabetes, and chronic kidney disease, while emerging evidence also implicates ApoM in neurovascular, inflammatory, and retinal disorders. This evidence concerns the gene APOM and Insulin resistance.